Moreover, doxorubicin treatment increased the nuclear retention and UBE2L3 promoter enrichment of HP1γ, subsequently promoting HP1γ-mediated silencing of UBE2L3 and increasing the p53 stability and activity in cisplatin-resistant cervical cancer cells. The gene discussed is UBE2L3; the disease is cervical cancer.